170 related articles for article (PubMed ID: 35267618)
1. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
[TBL] [Abstract][Full Text] [Related]
2. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract][Full Text] [Related]
3. PDL1 expression is an independent prognostic factor in localized GIST.
Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
[TBL] [Abstract][Full Text] [Related]
4. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
[TBL] [Abstract][Full Text] [Related]
5. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
[TBL] [Abstract][Full Text] [Related]
6. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
[TBL] [Abstract][Full Text] [Related]
7. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
8. CSPG4-targeting CAR-macrophages inhibit melanoma growth.
Greiner D; Xue Q; Waddell TQ; Kurudza E; Belote RL; Dotti G; Judson-Torres RL; Reeves MQ; Cheshier SH; Roh-Johnson M
bioRxiv; 2024 Jun; ():. PubMed ID: 38895447
[TBL] [Abstract][Full Text] [Related]
9. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
10. Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.
Harrer DC; Schenkel C; Berking C; Herr W; Abken H; Dörrie J; Schaft N
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291817
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
12. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.
Harrer DC; Schuler G; Dörrie J; Schaft N
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195686
[TBL] [Abstract][Full Text] [Related]
13. Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.
Pantaleo MA; Tarantino G; Agostinelli C; Urbini M; Nannini M; Saponara M; Castelli C; Stacchiotti S; Fumagalli E; Gatto L; Santini D; De Leo A; Marafioti T; Akarca A; Sabattini E; Pession A; Ardizzoni A; Indio V; Astolfi A
Oncoimmunology; 2019; 8(9):e1617588. PubMed ID: 31428517
[TBL] [Abstract][Full Text] [Related]
14. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
Rusakiewicz S; Semeraro M; Sarabi M; Desbois M; Locher C; Mendez R; Vimond N; Concha A; Garrido F; Isambert N; Chaigneau L; Le Brun-Ly V; Dubreuil P; Cremer I; Caignard A; Poirier-Colame V; Chaba K; Flament C; Halama N; Jäger D; Eggermont A; Bonvalot S; Commo F; Terrier P; Opolon P; Emile JF; Coindre JM; Kroemer G; Chaput N; Le Cesne A; Blay JY; Zitvogel L
Cancer Res; 2013 Jun; 73(12):3499-510. PubMed ID: 23592754
[TBL] [Abstract][Full Text] [Related]
15. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma.
Riccardo F; Tarone L; Iussich S; Giacobino D; Arigoni M; Sammartano F; Morello E; Martano M; Gattino F; Maria R; Ferrone S; Buracco P; Cavallo F
Ther Adv Med Oncol; 2019; 11():1758835919855491. PubMed ID: 31217827
[TBL] [Abstract][Full Text] [Related]
16. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
[TBL] [Abstract][Full Text] [Related]
18. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
[TBL] [Abstract][Full Text] [Related]
19. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
Front Immunol; 2017; 8():1911. PubMed ID: 29375561
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
Grossauer A; Uranowska K; Kitzwögerer M; Mostegel M; Breiteneder H; Hafner C
Oncol Lett; 2023 Sep; 26(3):382. PubMed ID: 37559576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]